<DOC>
	<DOCNO>NCT01681693</DOCNO>
	<brief_summary>The current study part large multi-investigator grant look pharmacogenetics number membrane transporter . The investigator study individual particular genotype human organic cation transporter , ( hOCT3 ) , multidrug toxin extrusion transporter , MATE1 test hypothesis genetic variation hOCT3 hMATE1 associate variation pharmacokinetics and/or pharmacodynamics antidiabetic agent , metformin .</brief_summary>
	<brief_title>Effect Genetic Variants MATE1 OCT3 Pharmacodynamics Metformin African Americans</brief_title>
	<detailed_description>To investigate potential association polymorphic genetic variant MATE1 OCT3 alter response metformin , genotype phenotype strategy employ . Specifically , investigator evaluate hypothesis African-Americans , population high incidence type 2 diabetes high variant allele frequency ( 44.5 % MATE1-66T &gt; C 11.3 % OCT3-81G &gt; delGA ) relative ethic group . To assess effect variant metformin response , investigator measure metformin renal clearance ( pharmacokinetics metformin ) , plasma glucose insulin level ( pharmacodynamic response ) healthy diabetic patient carry either reference variant allele .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Subjects selfidentify racial background , identify , parent four grandparent African American Subject status healthy volunteer In event diabetes indicate normal subject base OGTT result , notify patient ' primary care physician . SOPHIE cohort OR diagnosis T2DM base American Diabetes Association ( ADA ) criteria Subjects 18 year old 60 year Subjects healthy basis medical history , physical examination laboratory test healthy volunteer SOPHIE Subjects agree write informed consent participate study Unable confirm AfricanAmerican ethnicity Under 18 year old Pregnant lactating woman ( female subject urine pregnancy test screen visit ) . Prior history allergic reaction metformin Has risk congestive heart failure require pharmacologic treatment ( medical history ) Has prior history renal* hepatic dysfunction ( renal hepatic function evaluate base screen blood test conduct prior study enrollment ) Risk urinary gastric retention narrowangle glaucoma ( medical history examination ) Impaired renal function ( e.g suggest abnormal creatinine clearance , eGFR &lt; 60 serum creatinine &gt; 1.4 mg/dl female &gt; 1.5 mg/dl male ) may also result condition cardiovascular collapse ( shock ) , acute myocardial infarction ( heart attack ) , septicemia , abnormal heart rhythm ( tachyarrhythmias ; heart beat &gt; 100 beat per minute ) . Impaired hepatic function ( &gt; 1.5 time upper limit normal ) Evidence anemia ( hemoglobin &lt; 10 g ) Taking medication could confound study result , know substrate inhibitor OCT3 MATE1 , cimetidine . They provide consent participate study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>